Concepedia

Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients

Peter Ellis, R. Kaiser, Yihua Zhao, Peter Stopfer, Steve Gyorffy, Nasser H. Hanna

Clinical Cancer Research · 2010 · 96 citations · 30 references

DOIFull text

Open access

Abstract

The MTD of BIBF 1120 in combination with standard-dose pemetrexed was 200 mg bid. Continuous daily treatment with BIBF 1120 in this combination was tolerable, with promising signs of efficacy.

References

30

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Joan H. Schiller, David Harrington, Chandra P. Belani et al. · New England Journal of Medicine · 2002 · 4.9K citations

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

J Oan H. S Chiller, D Avid H Arrington, C Handra P. B Elani et al. · 2002 · 3.7K citations

, , +13